Hill-Rom (HRC) Rating Increased to Hold at Zacks Investment Research
Hill-Rom (NYSE:HRC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Hill-Rom exited the first quarter of fiscal 2019 on a strong note. The company saw a solid year-over-year increase in revenues on robust domestic growth, driven by sturdy performance by Patient Support Systems and Front Line Care. Hill-Rom has recorded around $100 million in new product revenues in the reported quarter. We are also upbeat about Hill-Rom’s integration of EarlySense’s continuous contact-free heart rate and respiratory rate sensing and analytics technology with its Centrella Smart+ bed platform in the reported quarter. Also, the tie-up with Microsoft to make advanced, relevant and actionable point-of-care data and solutions buoys optimism. Overall, Hill-Rom has outperformed its industry in the past three months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenues declined in the quarter.”
Other research analysts also recently issued reports about the company. UBS Group started coverage on Hill-Rom in a research note on Tuesday, November 27th. They issued a “buy” rating and a $115.00 price objective on the stock. ValuEngine downgraded Hill-Rom from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Raymond James boosted their price objective on Hill-Rom from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, November 5th. Barclays started coverage on Hill-Rom in a research note on Monday, October 15th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Finally, Morgan Stanley dropped their price objective on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Hill-Rom has a consensus rating of “Buy” and a consensus price target of $102.67.
Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, January 25th. The medical technology company reported $1.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.04. The firm had revenue of $683.50 million for the quarter, compared to the consensus estimate of $676.39 million. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.92 EPS. Equities research analysts expect that Hill-Rom will post 5.06 EPS for the current fiscal year.
In related news, SVP Andreas G. Frank sold 7,454 shares of the business’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total value of $713,795.04. Following the completion of the sale, the senior vice president now directly owns 27,224 shares of the company’s stock, valued at approximately $2,606,970.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.73% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. BOKF NA increased its position in Hill-Rom by 51.9% in the 4th quarter. BOKF NA now owns 37,800 shares of the medical technology company’s stock valued at $3,347,000 after buying an additional 12,919 shares in the last quarter. American International Group Inc. increased its position in Hill-Rom by 1.6% in the 4th quarter. American International Group Inc. now owns 137,381 shares of the medical technology company’s stock valued at $12,165,000 after buying an additional 2,138 shares in the last quarter. Geode Capital Management LLC increased its position in Hill-Rom by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 647,698 shares of the medical technology company’s stock valued at $57,353,000 after buying an additional 26,781 shares in the last quarter. Captrust Financial Advisors increased its position in Hill-Rom by 166.3% in the 4th quarter. Captrust Financial Advisors now owns 783 shares of the medical technology company’s stock valued at $69,000 after buying an additional 489 shares in the last quarter. Finally, Fort L.P. increased its position in Hill-Rom by 135.7% in the 4th quarter. Fort L.P. now owns 14,229 shares of the medical technology company’s stock valued at $1,260,000 after buying an additional 8,192 shares in the last quarter. 86.96% of the stock is owned by institutional investors and hedge funds.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.